Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 637

1.

Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation.

Sorensen SV, Dewilde S, Singer DE, Goldhaber SZ, Monz BU, Plumb JM.

Am Heart J. 2009 Jun;157(6):1064-73. doi: 10.1016/j.ahj.2009.03.022.

PMID:
19464418
2.
3.
4.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.

Kamel H, Johnston SC, Easton JD, Kim AS.

Stroke. 2012 Mar;43(3):881-3. doi: 10.1161/STROKEAHA.111.641027. Epub 2012 Feb 3.

5.

Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation? A cost-utility analysis.

Quinn RR, Naimark DM, Oliver MJ, Bayoumi AM.

Am J Kidney Dis. 2007 Sep;50(3):421-32.

PMID:
17720521
6.
7.
8.

Guidelines for stroke prevention in patients with atrial fibrillation.

Howard PA.

Drugs. 1999 Dec;58(6):997-1009. Review.

PMID:
10651387
9.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.

Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP.

Ann Intern Med. 2011 Jan 4;154(1):1-11. doi: 10.7326/0003-4819-154-1-201101040-00289. Epub 2010 Nov 1.

PMID:
21041570
10.

Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.

Coleman CI, Straznitskas AD, Sobieraj DM, Kluger J, Anglade MW.

Am J Cardiol. 2012 Apr 1;109(7):1020-5. doi: 10.1016/j.amjcard.2011.11.034. Epub 2012 Jan 3.

PMID:
22221944
12.

A review of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation.

Abdelhafiz AH.

Clin Ther. 2001 Oct;23(10):1628-36. Review.

PMID:
11727726
13.

Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study.

Menzin J, Boulanger L, Hauch O, Friedman M, Marple CB, Wygant G, Hurley JS, Pezzella S, Kaatz S.

Ann Pharmacother. 2005 Mar;39(3):446-51. Epub 2005 Feb 8.

PMID:
15701783
14.
15.

Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation.

Catherwood E, Fitzpatrick WD, Greenberg ML, Holzberger PT, Malenka DJ, Gerling BR, Birkmeyer JD.

Ann Intern Med. 1999 Apr 20;130(8):625-36.

PMID:
10215558
17.

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective.

Sorensen SV, Kansal AR, Connolly S, Peng S, Linnehan J, Bradley-Kennedy C, Plumb JM.

Thromb Haemost. 2011 May;105(5):908-19. doi: 10.1160/TH11-02-0089. Epub 2011 Mar 22.

PMID:
21431243
19.

Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.

Lee S, Anglade MW, Meng J, Hagstrom K, Kluger J, Coleman CI.

Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):472-9. doi: 10.1161/CIRCOUTCOMES.112.965251. Epub 2012 Jun 26.

20.
Items per page

Supplemental Content

Write to the Help Desk